Herpes Zoster Market Research Report – Global Forecast till 2027

Herpes Zoster Market Research Report: by Diagnosis (laboratory testing, and others), Treatment and Prevention (Antiviral, Narcotic, Anti-Inflammatory, Antihistamines, Vaccines), Route of Administration (oral, others), by End user - Global Forecast Till 2027

ID: MRFR/HC/5671-HCR | February 2021 | Region: Global | 90 pages

Market Scenario:


Global Herpes Zoster Market is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 12.7% over the forecast period. Herpes Zoster, also known as shingles, is a viral disease caused by reactivation of varicella-zoster virus. It manifests as a result of reactivation of the varicella virus laid dormant in the sensory ganglion following a chicken pox infection early in life or occasionally in utero. Post herpetic neuralgia (PHN) is one of the most troublesome complications which is very tiring to the patient as well as to the physician.


Extensive research and development activities is one of the key factors driving the Herpes Zoster market. On October 23, 2017, GlaxoSmithKline plc received FDA approval for Zoster Vaccine Recombinant i.e. Shingrix, for the prevention of herpes zoster in adults aged 50 years and older. Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses. Apart from this there are many treatment approaches are under clinical trials for the treatment of Herpes Zoster. For instance, ASP2151 drug by Maruho Co., Ltd. and Asahi Kasei Pharma Corp. is under phase-3 clinical trial for the treatment of patients affected with Herpes Zoster.


Various other factors such as technological advancements, geriatric population, favourable reimbursement and funding policies in developed countries, and developing healthcare infrastructure are also expected to propel the growth of the market. However, high cost of vaccine and medications, lack of awareness of the disease among physicians in developing or underdeveloped countries, diverse range of symptoms, and other complications can hinder the market growth over the forecast period.


Segmentation:


The Global Herpes Zoster Market has been segmented into diagnosis, treatment & prevention, route of administration and end user.


The market, based on diagnosis, has been segmented into laboratory testing and others. The laboratory testing is further classified as immunofluorescent microscopy, real-time polymerase chain reaction (PCR), and serological testing.


The market, by treatment and prevention, has been segmented into diagnosis and treatment. The diagnosis segment is further classified as antiviral medications, narcotic medications, anti-inflammatory medications, antihistamines, anticonvulsants, capsaicin, numbing creams, gels, or patches, vaccines and others.


The market, by route of administration, has been segmented into oral, topical and others.


The market, by end user, has been segmented into hospitals & clinics, diagnostic centres, research & academic institutes, home care settings and others.


The hospitals and clinics segment is anticipated to hold the largest market share owing to increase in hospitalizations. The diagnostic centers are expected to grow at the highest CAGR owing to the increasing demand for modern healthcare facilities.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The herpes zoster market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European Herpes Zoster Market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The Herpes Zoster Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Herpes Zoster market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Herpes Zoster Market Share (%), by Region, 2017


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Report.


Geographically, the Americas is anticipated to dominate the global herpes zoster market owing to increasing cases of herpes zoster, rising healthcare expenditure, geriatric population and technological advancements in herpes zoster. According to a 2017 study published in the Infectious Disease Clinics journal, more than 1 million cases of herpes zoster are registered in the United States every year which costs around USD 5 billion annually.


Europe is expected to hold the second largest position in the global herpes zoster market. The market growth in this region is attributed to the government funding and improvement in research & development activities. In Europe, the annual incidence of herpes zoster varies from 2.0 to 4.6/1 000 and the overall incidence of herpes zoster is found to be increasing linearly.


The herpes zoster market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing awareness about the vaccines and rising healthcare spending.


The Middle East & Africa are expected to hold the least share of the market due to lack of awareness about the condition.


Global Herpes Zoster Market, by Diagnosis:



  • Laboratory Testing

    • Immunofluorescent Microscopy

    • Real-Time Polymerase Chain Reaction (PCR)

    • Serological Testing

    • Others




Global Herpes Zoster Market, by Treatment and Prevention:



  • Laboratory Testing

  • Antiviral Medications

  • Narcotic Medications

  • Anti-Inflammatory Medications

  • Antihistamines

  • Anticonvulsants

  • Capsaicin

  • Numbing Creams, Gels, or Patches

  • Vaccines

  • Others


Global Herpes Zoster Market, by Route of Administration:



  • Oral

  • Topical

  • Others


Global Herpes Zoster Market, by End User:



  • Hospitals & Clinics

  • Diagnostic Centres

  • Research & Academic Institutes

  • Home Care Settings

  • Others 


Global Herpes Zoster Market, by Region:



  • Americas

  • North America

  • US

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe

  • Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • The Middle East & Africa

  • Middle East

  • Africa


Global Herpes Zoster Market, by Key Players



  • Astellas Pharma Inc.

  • Foamix Pharmaceuticals

  • GeneOne Life Science

  • GlaxoSmithKline plc

  • Merck & Co.

  • NAL Pharma

  • Novartis AG

  • Hoffmann-La Roche Ltd

  • TSRL, Inc.


Intended Audience



  • Research and Development Organization

  • Diagnostic Laboratories

  • Healthcare Organizations

  • Academics and Research Institutes

  • Pharmaceutical Companies



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   12.7% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment & prevention, Route of administration and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Astellas Pharma Inc., Foamix Pharmaceuticals, GeneOne Life Science, GlaxoSmithKline plc, Merck & Co., NAL Pharma, Novartis AG, Hoffmann-La Roche Ltd, TSRL, Inc.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   Extensive research and development activities


Frequently Asked Questions (FAQ) :


The herpes zoster market would record a CAGR of 12.7% during the forecast period of 2018 to 2023.

Leading factors like the geriatric population, favorable reimbursement & funding policies in developed countries, technological advancements, and improving healthcare infrastructure would trigger market growth for the herpes zoster market.

The herpes zoster market study includes oral, topical, and others as the route of administrations.

The Americas would top the herpes zoster market.

The Asia Pacific region would be the fastest-growing herpes zoster market.

Table of Contents:


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Macroeconomic Indicators

4.5 Pipeline Products

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Herpes Zoster Market, by Diagnosis

6.1 Introduction

6.2 Laboratory Testing

6.2.1 Immunofluorescent Microscopy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2 Real-Time Polymerase Chain Reaction (PCR)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3 Serological Testing

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Herpes Zoster Market, by Treatment and Prevention

7.1 Introduction

7.2 Antiviral Medications

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Narcotic Medications

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Anti-Inflammatory Medications

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Antihistamines

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Anticonvulsants

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.7 Capsaicin

Market Estimates & Forecast, by Region, 2020–2023

Market Estimates & Forecast, by Country, 2020-2027

7.8 Numbing Creams, Gels, or Patches

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.9 Vaccines

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.10 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Herpes Zoster Market, by Route of Administration

8.1 Introduction

8.2 Oral

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Topical

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Herpes Zoster Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4 Research & Academic Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.5 Home Care Settings

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.6 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 10. Global Herpes Zoster Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 ASTELLAS PHARMA INC.

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 FOAMIX PHARMACEUTICALS

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 GENEONE LIFE SCIENCE

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 GlaxoSmithKline plc

12.4.1 Company Overview

12.4.2 Product Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Merck & Co.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 NAL Pharma

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Novartis AG

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 F. HOFFMANN-LA ROCHE LTD

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 TSRL, Inc.

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Herpes Zoster Industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Global Herpes Zoster Market Synopsis, 2020-2027

Table 2 Global Herpes Zoster Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Herpes Zoster Market, by Region, 2020-2027 (USD Million)

Table 4 Global Herpes Zoster Market, by Diagnosis, 2020-2027 (USD Million)

Table 5 Global Herpes Zoster Market, by Treatment and Prevention, 2020-2027 (USD Million)

Table 6 Global Herpes Zoster Market, by Route of Administration, 2020-2027 (USD Million)

Table 7 Global Herpes Zoster Market, by End User, 2020-2027 (USD Million)

Table 8 North America: Herpes Zoster Market, by Diagnosis, 2020-2027 (USD Million)

Table 9 North America: Herpes Zoster Market, by Treatment and Prevention, 2020-2027 (USD Million)

Table 10 Global Herpes Zoster Market, by Route of Administration, 2020-2027 (USD Million)

Table 11 North America: Herpes Zoster Market, by End User, 2020-2027 (USD Million)

Table 12 US: Herpes Zoster Market, by Diagnosis, 2020-2027 (USD Million)

Table 13 US: Herpes Zoster Market, by Treatment and Prevention, 2020-2027 (USD Million)

Table 14 Global Herpes Zoster Market, by Route of Administration, 2020-2027 (USD Million)

Table 15 US: Herpes Zoster Market, by End User, 2020-2027 (USD Million)

Table 16 Canada: Herpes Zoster Market, by Diagnosis, 2020-2027 (USD Million)

Table 17 Canada: Herpes Zoster Market, by Treatment and Prevention, 2020-2027 (USD Million)

Table 18 Canada: Herpes Zoster Market, by End User, 2020-2027 (USD Million)

Table 19 South America: Herpes Zoster Market, by Diagnosis, 2020-2027 (USD Million)

Table 20 South America: Herpes Zoster Market, by Treatment and Prevention, 2020-2027 (USD Million)

Table 21 Global Herpes Zoster Market, by Route of Administration, 2020-2027 (USD Million)

Table 22 South America: Herpes Zoster Market, by End User, 2020-2027 (USD Million)

Table 23 Europe: Herpes Zoster Market, by Diagnosis, 2020-2027 (USD Million)

Table 24 Europe: Herpes Zoster Market, by Treatment and Prevention, 2020-2027 (USD Million)

Table 25 Europe: Herpes Zoster Market, by End User, 2020-2027 (USD Million)

Table 26 Western Europe: Herpes Zoster Market, by Diagnosis, 2020-2027 (USD Million)

Table 27 Western Europe: Herpes Zoster Market, by Treatment and Prevention, 2020-2027 (USD Million)

Table 28 Global Herpes Zoster Market, by Route of Administration, 2020-2027 (USD Million)

Table 29 Western Europe: Herpes Zoster Market, by End User, 2020-2027 (USD Million)

Table 30 Eastern Europe: Herpes Zoster Market, by Diagnosis, 2020-2027 (USD Million)

Table 31 Eastern Europe: Herpes Zoster Market, by Treatment and Prevention, 2020-2027 (USD Million)

Table 32 Global Herpes Zoster Market, by Route of Administration, 2020-2027 (USD Million)

Table 33 Eastern Europe: Herpes Zoster Market, by End User, 2020-2027 (USD Million)

Table 34 Asia-Pacific: Herpes Zoster Market, by Diagnosis, 2020-2027 (USD Million)

Table 35 Asia-Pacific: Herpes Zoster Market, by Treatment and Prevention, 2020-2027 (USD Million)

Table 36 Global Herpes Zoster Market, by Route of Administration, 2020-2027 (USD Million)

Table 37 Asia-Pacific: Herpes Zoster Market, by End User, 2020-2027 (USD Million)

Table 38 Middle East & Africa: Herpes Zoster Market, by Diagnosis, 2020-2027 (USD Million)

Table 39 Middle East & Africa: Herpes Zoster Market, by Treatment and Prevention, 2020-2027 (USD Million)

Table 40 Global Herpes Zoster Market, by Route of Administration, 2020-2027 (USD Million)

Table 41 Middle East & Africa: Herpes Zoster Market, by End User, 2020-2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Market Structure for Global Herpes Zoster Market

Figure 3 Market Dynamics for Global Herpes Zoster Market

Figure 4 Global Herpes Zoster Market Share, by Diagnosis, 2020

Figure 5 Global Herpes Zoster Market Share, by Treatment and Prevention, 2020

Figure 6 Global Herpes Zoster Market Share, by Treatment and Prevention, 2020

Figure 7 Global Herpes Zoster Market Share, by End User, 2020

Figure 8 Global Herpes Zoster Market Share, by Region, 2020

Figure 9 North America: Herpes Zoster Market Share, by Country, 2020

Figure 10 Europe: Herpes Zoster Market Share, by Country, 2020

Figure 11 Asia-Pacific: Herpes Zoster Market Share, by Country, 2020

Figure 12 Middle East & Africa: Herpes Zoster Market Share, by Country, 2020

Figure 13 Global Herpes Zoster Market: Company Share Analysis, 2020 (%)

Figure 14 ASTELLAS PHARMA INC.: Key Financials

Figure 15 ASTELLAS PHARMA INC.: Segmental Revenue

Figure 16 ASTELLAS PHARMA INC.: Geographical Revenue

Figure 17 FOAMIX PHARMACEUTICALS: Key Financials

Figure 18 FOAMIX PHARMACEUTICALS: Segmental Revenue

Figure 19 FOAMIX PHARMACEUTICALS: Geographical Revenue

Figure 20 GENEONE LIFE SCIENCE: Key Financials

Figure 21 GENEONE LIFE SCIENCE: Segmental Revenue

Figure 22 GENEONE LIFE SCIENCE: Geographical Revenue

Figure 23 GlaxoSmithKline plc: Key Financials

Figure 24 GlaxoSmithKline plc: Segmental Revenue

Figure 25 GlaxoSmithKline plc: Geographical Revenue

Figure 26 Merck & Co.: Key Financials

Figure 27 Merck & Co.: Segmental Revenue

Figure 28 Merck & Co.: Geographical Revenue

Figure 29 NAL Pharma: Key Financials

Figure 30 NAL Pharma: Segmental Revenue

Figure 31 NAL Pharma: Geographical Revenue

Figure 32 Novartis AG: Key Financials

Figure 33 Novartis AG: Segmental Revenue

Figure 34 Novartis AG: Geographical Revenue

Figure 35 F. HOFFMANN-LA ROCHE LTD: Key Financials

Figure 36 F. HOFFMANN-LA ROCHE LTD: Segmental Revenue

Figure 37 F. HOFFMANN-LA ROCHE LTD: Geographical Revenue

Figure 38 TSRL, Inc.: Key Financials

Figure 39 TSRL, Inc.: Segmental Revenue

Figure 40 TSRL, Inc.: Geographical Revenue



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.